Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising drug may reduce eye bulging in thyroid disease

NCT ID NCT06106828

Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times

Summary

This study tests a drug called satralizumab in 127 people with moderate-to-severe thyroid eye disease, a condition that causes eye bulging and discomfort. Participants receive either the drug or a placebo to see if it reduces eye bulging by at least 2 millimeters over 24 weeks. The goal is to find a safer, non-surgical treatment option.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

127 people

The number who actually took part.

Started

Nov 2023

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- Clinical diagnosis of TED based on CAS Exclusion Criteria: * Decrease in CAS or proptosis of \>≥ 2 points or ≥ 2 mm, respectively, in the study eye between Screening and Study Baseline (Day 1) * Requiring immediate surgical ophthalmological intervention or planning corrective surgery or irradiation during the course of the study, in the judgment of the investigator * Identified pre-existing ophthalmic disease that, in the judgment of the investigator, would preclude study participation or complicate interpretation of study results, including corneal decompensation unresponsive to medical management and including ophthalmic diseases that will likely require prohibited therapy during the study * Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes an individual's safe participation in and completion of the study * Pregnant or breastfeeding, or intention of becoming pregnant during the study or within 3 months after the final dose of satralizumab

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Thyroid eye disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos Graves Ophthalmopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Thyroid eye disease

Contacts and locations

Locations

  • AIBILI - Association for Innovation and Biomedical Research on Light

    Coimbra, 3000-548, Portugal

  • Beijing Hospital of Ministry of Health

    Beijing, 100730, China

  • Beijing Tongren Hospital, Capital Medical University

    Beijing, 100730, China

  • Bristol Eye Hospital

    Bristol, BS1 2LX, United Kingdom

  • CHNO Hopital des Quinze Vingts

    Paris, 75012, France

  • CHU Nantes - Hotel Dieu

    Nantes, 44093, France

  • Chung-Ang University Hospital

    Seoul, 06973, South Korea

  • Connecticut Eye Consultants, P.C.

    Danbury, Connecticut, 06810, United States

  • Fondation Rothschild

    Paris, 75019, France

  • Gartnavel General Hospital

    Glasgow, G12 0YN, United Kingdom

  • Hadassah MC

    Jerusalem, 9112001, Israel

  • Hospital Ramon y Cajal

    Madrid, 28031, Spain

  • Hospital Universitari de Bellvitge

    L'Hospitalet de Llobregat, Barcelona, 8907, Spain

  • Hospital Universitario Clínico San Carlos

    Madrid, 28040, Spain

  • Hospital Universitario Vall d Hebron

    Barcelona, 08035, Spain

  • Hospital Universitario Virgen de la Macarena

    Seville, 41007, Spain

  • Hospital Universitario Virgen de las Nieves

    Granada, 18012, Spain

  • Hospital Universitario la Fe: Servicio de Oftalmologia

    Valencia, 46026, Spain

  • Maidstone Hospital

    Maidstone, Kent, ME16 9QQ, United Kingdom

  • Moorfields Eye Hospital NHS Foundation Trust

    London, EC1V 2PD, United Kingdom

  • Peking Union Medical College Hospital

    Beijing, 100032, China

  • Peking University Third Hospital

    Beijing, 100191, China

  • Plastics-Orbit-Neuro

    San Diego, California, 92108, United States

  • Profesorskie Centrum Medyczne Spolka Z Ograniczona Odpowiedzialnoscia

    Gdansk, 80-180, Poland

  • Rabin MC

    Petah Tikva, 4941492, Israel

  • Retina Consultants of Texas

    San Antonio, Texas, 78251, United States

  • Royal Liverpool University Hospital

    Liverpool, L7 8XP, United Kingdom

  • Samsung Medical Center

    Seoul, 135-710, South Korea

  • Scheie Eye Institute

    Philadelphia, Pennsylvania, 19104, United States

  • Seoul National University Bundang Hospital

    Seongnam-si, 13620, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, 003-722, South Korea

  • Sheba medical center

    Ramat Gan, Israel

  • Specjalistyczny Osrodek Okulistyczny Oculomedica

    Bydgoszcz, 85-316, Poland

  • St James University Hospital

    Leeds, LS9 7TF, United Kingdom

  • Sussex Eye Hospital

    Brighton, BN2 5BF, United Kingdom

  • Toronto Retina Institute

    Toronto, Ontario, M3C 0G9, Canada

  • Universite de Montreal - Hopital Maisonneuve-Rosemont

    Montreal, Quebec, H1T 2M4, Canada

  • University of Alberta

    Edmonton, Alberta, Canada

  • University of Illinois Eye and Ear Infirmary

    Chicago, Illinois, 60612, United States

  • Vanderbilt Eye Institute

    Nashville, Tennessee, 37232-8808, United States

  • Xi'an Fourth Hospital

    Xi'an, 710004, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.